Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by oilandgasmanon Nov 02, 2021 12:27pm
117 Views
Post# 34077770

RE:RE:I've had a nice...

RE:RE:I've had a nice...
GoldMemberT wrote:

nothing bad?

they pulled a fast one for a financing and haven't had a significant non fluff piece of news since. That in and of itself is just akin spitting in investors faces.

they haven't spun out dialco as promised

they don't have a partner that they claimed they would have for Dialco.

no news on continued "heightened enrolment"

no start of dimi trial

Did not live up to promise of 15 hospitals by end of Q3

investor presentation says 60% enrolment for PMX by DECEMBER but on clinicaltrials.gov it's slated for March (I bet that will get moved too). 

literally can not get the company to pick up their phone which actually aside from here does not exist anywhere else. Even the worst of companies have someone for investors to talk to. Most of the time the CEO does it to save on cost but in this case they can't even spend 50k on a recent grad. 
 

 

mercedesman wrote: ...run on my Crypto's of late...

...so I'm putting some of the profits into some undervalued stocks...

...EDT seems like a good bet with it being 35% off the financing price, and 50% off the price it was trading at,  in the days leading up to the latest bought deal financing by AGP...all with quite heavy insider participation.

A few good things have happened since we last traded at these levels in 2018 and 2017

For example I believe that the last time we traded at these levels ... was well before:

 

  • Baxter distribution contract (derisking of Tigris, and cost covering)
  • Kellum hired as CMO
  • "Confirmatory" Phase 3b, 2:1, baysian, open label Trial
  • SAMI FDA & HC approvals
  • Golden Hour seminal article by Ronco (advocating for EAA and PMX-HP)
  • World Sepsis Alliance talk & keynote acknowledgement of Spectral at Vincenza
  • US presidential push towards Home Dialysis
  • Outset and NxStage valuations of > $ 2B for their HD pumps
  • Possibe benefit of PMX in treatment of Covid recently acknowledged by Kellum
  • Lots more RWE for PMX-HP
  • some dosing rationale on why the Euphrates results could have been better even outside the new target sub-group (filter capcity, duration, # filters, etc.)
  • a demonstrated appetite for blood filtration devices in the US (se AEMD and CTSO) - even ones far less advanced (in terms of FDA approval) than Spectral.
 Nothing else negative has happened that I can determine, other than a continuation of the silence.


MM




Amen ..Shitshow, it makes me sick given the words i've been told.














<< Previous
Bullboard Posts
Next >>